Healthcare Roundup – Adamis Pharma soars on Tempol IND submission for COVID-19 treatment; MindMed kicks off early stage trial for LSD-MDMA cocktail

Published on: January 20, 2021
Author: Amy Liu

Adamis Pharma soars on Tempol IND submission for COVID-19 treatment

Adamis Pharmaceuticals (NASDAQ:ADMP) gains 35% in premarket after submitting an Investigational New Drug (IND) application to FDA for Tempol, as a potential treatment for COVID-19.

The submission followed a Pre-IND meeting in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol.

Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity in preclinical studies.

The company in-licensed global rights to Tempol from Matrix Biomed for the treatment of respiratory diseases, including COVID-19, in addition to a dermatology indication: preventing radiation dermatitis in patients undergoing treatment for cancer, in June last year.

MindMed kicks off early stage trial for LSD-MDMA cocktail

MindMed (OTCQB:MMEDF) starts an early stage trial to test the effects of combining psychedelic substance LSD and party drug MDMA in an effort to reduce the negative emotions and anxiety that are sometimes associated with LSD when used in therapy or clinical settings.

MindMed aims to understanding how to balance both MDMA and LSD in a cohesive way to create better patient outcomes, and develop more advanced psychedelic assisted therapies.The study is expected to take about one year to complete.

The Phase 1 double-blind, placebo-controlled, 4-period crossover design study will assess subjective and autonomic effects aiming to determine the qualitative emotional differences between a combined MDMA and LSD experience, a pure LSD experience and a pure MDMA experience, versus a placebo.

Ionis, UCSD team up to test antisense candidate in treatment-resistant blood cancer

According to Eurekalert article, Ionis (IONS +2.6%) will be applying its antisense oligonucleotide technology to the blood cancer multiple myeloma (MM), and it has positive results in mouse models that it says support a recently launched phase 1 trial to evaluate the candidate, ION251.

Ionis has teamed up with the University of California, San Diego (UCSD), to inhibit IRF4, which promotes the growth and proliferation of the cancer cells, using an antisense oligonucleotide.

As per preclinical data reported in journal Cell Stem Cell, ION251 significantly cut levels of MM cells and enhanced survival in mouse models.

The antisense drug was tested for six weeks in the mouse models of MM, administering one dose per day for a week, followed by three doses per week. More than 70% of the treated mice survived the cancer, compared to none in control group.

The researchers also studied cells from multiple myeloma patients and from healthy donors. ION251 eradicated multiple myeloma stem cells but left healthy blood cells alone.

Biotechnology COVID-19 Healthcare Services Life Science